Delivery Order SPE2DB22D1200-SPE2DB25FN3NP
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vaxneuvance 0.5 mL syringes valued at $1,370.34 on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price contract represents a non-competitive set-aside and will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $17,804.46 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Vaxneuvance 0.5 mL syringes. This is a firm fixed price, competitively awarded contract with an ultimate completion date of July 22, 2025, and will be performed in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Vaxneuvance 0.5 ML syringes, valued at $7,899.85. This firm fixed-price delivery order is scheduled for completion by July 22, 2025, with performance taking place at the company's corporate office in Conshohocken, Pennsylvania. The award was competitively awarded without a set-aside designation, reflecting AmerisourceBergen's capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a $6,512.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Vaxneuvance 0.5 mL syringes on August 4, 2025, with an ultimate completion date of August 5, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion and extending through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vaxneuvance 0.5 ML syringes, with a contract ceiling value of $2,740.78. The award was issued on July 31, 2025, with an ultimate completion date of August 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating the contract was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which is also the location of...
- The Defense Logistics Agency awarded a delivery order valued at $22,419.56 to AmerisourceBergen Drug Corp for the supply of Vaxneuvance 0.5 ML syringes on August 4, 2025, with an ultimate completion date of August 5, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Vaxneuvance is a pneumococcal vaccine indicated for immunization against invasive pneumococcal...
- The Defense Logistics Agency awarded a delivery order valued at $58,226.32 to AmerisourceBergen Drug Corp for the supply of Vaxneuvance 0.5 mL syringes. This firm fixed-price contract, issued on July 31, 2025, represents a non-set-aside award made through open competition. The work will be performed in Conshohocken, Pennsylvania, with an ultimate completion date of August 1, 2025. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of VAXNEUVANCE 0.5 ML syringes valued at $20,438.65 with a firm fixed price contract type. This order is expected to be completed by July 21, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award was made through a competitive process with no set-aside designation, reflecting AmerisourceBergen's proven capability to meet federal...
- The Defense Logistics Agency (DLA) awarded a $10,638.89 delivery order to AmerisourceBergen Drug Corp for VAXNEUVANCE 0.5 ML syringes on July 29, 2025, with completion targeted for July 30, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is performing the work at its corporate office location. The delivery order represents pharmaceutical procurement to support federal medical supply...
- The Defense Logistics Agency awarded a $67,246 delivery order to Amerisourcebergen Drug Corporation to supply 0.5 milliliter syringes of Vaxneuvance vaccine. The firm fixed price order is being fulfilled from the contractor's facility in Conshohocken, Pennsylvania for delivery between August 11-14, 2023. As a major distributor of pharmaceuticals and medical supplies for the Department of Defense, Amerisourcebergen is well positioned to efficiently provide these vaccines in support of the...
- SPE2DB22D1200Indefinite Delivery Contract
- SPE2DB22D1200-SPE2DB25FN3NPDelivery Order
The Defense Logistics Agency awarded a $7,582.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Vaxneuvance 0.5 mL syringes on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999,999,999 global pharmaceutical support vehicle valued through December 2026. The contract will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. Vaxneuvance is a pneumococcal vaccine product used in military and federal healthcare settings. This delivery order exemplifies AmerisourceBergen's ongoing role as a critical pharmaceutical distributor for the Department of Defense medical supply chain, supplying vaccines, specialty medications, and medical devices to support military healthcare operations. AmerisourceBergen's extensive federal procurement portfolio and demonstrated capability in competitive contracting have established the company as a primary vendor for federal medical supply needs across multiple therapeutic domains and geographic regions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.6k | 8/1/25 |